Endocrine Health Foundation,
ASCPT Workshop Orlando FL 2005, "Interaction of Drugs with Estrogen Endocrinology" [pictured above]
Laura Kragie MD, "Introduction and Background"
Jeffrey Dodge PhD, "An Illustrative Example of the Identification of a New SERM Targeted to Affect the Hypothalamic-Pituitary-Ovarian Axis"
David Stresser PhD, "High Throughput Testing for Inhibition of p450s Including Aromatase (CYP19) and Overview of the EPA's Endocrine Disruptor Screening Program"
David Flockhart MD PhD, "Overview of Estrogen and p450 Drug Metabolism, Drug Interactions, and Pharmacogenomics of Aromatase"
Eugene Albrecht PhD, "Role of Estrogen and Aromatase in Pregnancy and Fetal Gonadal Development"
LEARNING OBJECTIVES: Understand the process of tissue generated estrogen from circulating androgen precursors/prohormones and consequences of inhibiting the in situ production of estrogen, in men, women, fetus and child. Review in vitro screening tools for endocrine disruptors of estrogenic production/receptor cascade, and the EPAs Endocrine Disruptor Screening Testing Advisory Committee (EDSTAC) guidelines. Examine the interaction of drugs with the Hypothalamic -Pituitary-Ovarian (HPO) axis and estrogen cascade as illustrated by the history of a new Selective Estrogen Modulator (SERM) targeted to treat gynecologic conditions.
Seminar Merck Pharmaceuticals, Wayne NJ, "Azole Aromatase Inhibitors and their
Clinical Implications" 2005: Laura Kragie MD
© 2001- 2008 Endocrine Health Fdn (tm) All rights reserved.
email Endocrine Health Fdn: EFH at endocrinehealth.org